Cigna Corporation

🇺🇸New York Stock Exchange
Back to all articles
Cigna Corporation stock analysis CI overview
Bullish +75

Cigna Q1 Earnings Beat Estimates on Strong Evernorth Unit

📈 Cigna Group reported first-quarter 2026 adjusted EPS of $7.79, beating analyst estimates by 2.2%.

📊 Bottom-line earnings improved 15.6% year over year as the total bottom line beat expectations.

🔄 Adjusted revenues grew 4.7% year over year to reach $68.5 billion, surpassing consensus projections.

🏥 The Evernorth Health Services segment drove performance with a growing membership base and higher specialty volumes.

⚠️ Strongevernorth gains were partially offset by rising pharmacy costs and sharp revenue declines in Cigna Healthcare.

👥 Cigna's medical customer base totaled 18.3 million as of March 31, 2026, up 1.6% year over year.

💰 Total benefits and expenses increased 4% year over year to $66.1 billion due to higher pharmacy and service costs.

🛠️ Adjusted SG&A expense ratio improved 100 basis points year over year to 4.8% driven by operational efficiency.

🚀 Adjusted income from operations totaled $2.1 billion, advancing 12% year over year on strong segment contributions.

💊 Evernorth Health Services revenues rose 9% year over year to $58.4 billion due to drug mix and volume improvements.

📉 Pre-tax margins in Evernorth deteriorated 20 basis points year over year to 2.5% despite solid organic growth.

📉 Cigna Healthcare revenue dropped 21% year over year to $11.5 billion following the HCSC transaction.

💵 Despite revenue decline, Cigna Healthcare pre-tax operating income improved 18% year over year to $1.5 billion.

🏦 The medical care ratio (MCR) increased to 79.8% for the quarter and reached 83.7-84.7% for the full year projection.

💵 Cigna holds $7 billion in cash and equivalents, down 8.3% from the end of 2025, with total assets at $153.3 billion.

📉 Operating cash flow plunged 41% year over year to $1.1 billion in the first quarter.

🎯 Management raised full-year adjusted EPS guidance to a minimum of $30.35, representing at least 1.7% growth.

👁️ Zacks Rank #3 (Hold) and similar top performers include UnitedHealth Group, Elevance Health, and Humana.

Bullish Signals
  • Cigna Group reported first-quarter adjusted earnings per share of $7.79, beating the Zacks Consensus Estimate by 2.2%.
  • Adjusted revenues grew 4.7% year over year to $68.5 billion, with the top line exceeding consensus estimates by 2.7%.
  • The medical customer base reached 18.3 million as of March 31, 2026, surpassing the Zacks Consensus Estimate of 18.1 million due to strong performance in Middle, Select, and International markets.
  • Adjusted income from operations totaled $2.1 billion, advancing 12% year over year driven by higher contributions from Cigna Healthcare and Evernorth Health Services segments.
  • Cigna's adjusted SG&A expense ratio improved 100 basis points year over year to 4.8%, demonstrating better operational efficiency and a beneficial shift in business mix.
  • The Evernorth Health Services segment saw adjusted revenues rise 9% year over year to $58.4 billion, driven by solid organic growth in specialty businesses and improved specialty volumes.
  • Cigna Healthcare pre-tax adjusted operating income improved 18% year over year to $1.5 billion, which was higher than the Zacks Consensus Estimate of $1.4 billion.
  • Medical Care Ratio (MCR) improved 240 basis points year over year to 79.8%, resulting from the HCSC transaction and higher margins across U.S. Employer and Individual and Family Plan businesses.
  • Cigna reiterated positive long-term guidance, raising the adjusted EPS estimate for 2026 to a minimum of $30.35, representing growth of at least 1.7% from the 2025 reported figure.
  • The company raised its full-year adjusted operating income forecast for the Evernorth Health Services segment to a minimum of $6.9 billion and the Cigna Healthcare unit to $4.525 billion.
Risk Factors
  • Cigna's cash and cash equivalents declined 8.3% year over year to $7 billion, reducing liquidity buffers compared to the end of 2025.
  • Total assets contracted by 2.9% to $153.3 billion, shrinking the company's overall balance sheet from the previous year's level.
  • Operating cash flows plunged significantly by 41% year over year to just $1.1 billion, raising concerns about deteriorating cash generation capabilities.
  • The Cigna Healthcare segment suffered a sharp revenue decline of 21% year over year due to the Health Care Services Corporation (HCSC) transaction, negatively impacting top-line growth despite improved margins.
  • Adjusted operating income for the Evernorth Health Services unit marginally beat consensus but pre-tax margins deteriorated by 20 basis points to 2.5%, indicating pressure on profitability efficiency within the specialty and pharmacy business lines.
  • Total benefits and expenses increased 4% year over year, driven specifically by rising pharmacy and other service costs that are offsetting some of the revenue growth.
Full Analysis
Cigna Group (CI) reported first-quarter 2026 results that exceeded analyst expectations, driven primarily by strong performance from its Evernorth Health Services segment. The company posted adjusted earnings per share of $7.79, surpassing the Zacks Consensus Estimate by 2.2%, with total adjusted EPS growth of 15.6% year over year. Adjusted revenues increased 4.7% to $68.5 billion, aided by an expanding medical customer base that reached 18.3 million as of March 31, 2026, surpassing the consensus estimate of 18.1 million. Despite the overall beat, results were mixed across business units; the Evernorth Health Services segment saw adjusted revenues rise 9% to $58.4 billion due to pharmacy benefit services and specialty volume growth, though pre-tax margins slipped slightly to 2.5%. Conversely, Cigna Healthcare revenue declined sharply by 21% to $11.5 billion due to the sale of the Health Care Services Corporation (HCSC) transaction, although operating income improved 18% year over year to $1.5 billion driven by better margins in U.S. Healthcare plans. Company-wide benefits and expenses reached $66.1 billion, a 4% increase largely attributed to rising pharmacy costs. Financial position and guidance also reflect the quarter's outcomes, with cash and equivalents at $7 billion and total assets declining slightly to $153.3 billion due to the HCSC transaction proceeds. The company reiterated full-year 2026 guidance for adjusted EPS of at least $30.35, representing growth of at least 1.7% from the previous year, and maintained a medical care ratio (MCR) outlook between 83.7% and 84.7%. Operating cash flow dropped significantly to $1.1 billion, or 41% year over year, while adjusted operating income for the full year was raised slightly to a minimum of $7.95 billion. Cigna retains a Zacks Rank #3 (Hold) following the report.